Novel Arylazoarylmethane as Potential Inhibitor of Macrophage Migration Inhibitory Factor

He, Mingzhu; Metz, Christine N.; Cheng, Kai; Ling, Jie; Coleman, Thomas R.; VanPatten, Sonya; Al‐Abed, Yousef

doi:10.1002/ardp.201300243

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Future work capitalized on this discovery, and a number of inhibitor classes bearing key features of the dopachrome scaffold were reported and shown to attenuate diverse biological activities of MIF. − The most extensively studied of these is the isoxazole inhibitor ISO-1 ( 4 ), which was reported by Lubetsky et al in 2002 . While it is a modest inhibitor of tautomerase activity (most reports agree on an IC 50 value close to 18 μM), , it has been shown to inhibit many of MIF’s biological functions, including glucocorticoid overriding, nuclear translocation of NF-κB, cellular release, and cytokine-induced beta cell death .…”

Section: Mif Inhibitorsmentioning

confidence: 99%

Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor

Trivedi-Parmar

Jorgensen

2018

J. Med. Chem.

View full text Add to dashboard Cite

Macrophage migration inhibitory factor (MIF) is an upstream regulator of the immune response whose dysregulation is tied to a broad spectrum of inflammatory and proliferative disorders. As its complex signaling pathways and pleiotropic nature have been elucidated, it has become an attractive target for drug discovery. Remarkably, MIF is both a cytokine and an enzyme that functions as a keto-enol tautomerase. Strategies including in silico modeling, virtual screening, high-throughput screening, and screening of anti-inflammatory natural products have led to a large and diverse catalogue of MIF inhibitors as well as some understanding of the structure-activity relationships for compounds binding MIF's tautomerase active site. With possible clinical trials of some MIF inhibitors on the horizon, it is an opportune time to review the literature to seek trends, address inconsistencies, and identify promising new avenues of research.

show abstract

Section: Mif Inhibitorsmentioning

confidence: 99%

Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor

Trivedi-Parmar

Jorgensen

2018

J. Med. Chem.

View full text Add to dashboard Cite

show abstract

“… 1 , 2 MIF is a member of the transferring growth factor-β (TGF-β) super family, which is expressed by a broad variety of cells, including B- and T-lymphocytes as well as endocrine, endothelial, and epithelial cells of diverse histogenetic origin. 3 Presently, MIF is considered to play an important role in the pro- and anti-inflammatory response to infection since it is constitutively expressed and acts as an upstream regulator of many other inflammatory cytokines. 4 , 5 …”

Section: Introductionmentioning

confidence: 99%

The association between the migration inhibitory factor -173G/C polymorphism and cancer risk: a meta-analysis

Zhou¹,

Weng²,

Wen³

et al. 2015

OTT

View full text Add to dashboard Cite

Previous studies have suggested that macrophage migration inhibitory factor (MIF) −173G/C polymorphism may be associated with cancer risk. However, previous research has demonstrated conflicting results. Therefore, we followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines and the meta-analysis on genetic association studies checklist, and performed a meta-analysis to investigate the association between MIF −173G/C polymorphisms and the risk of cancer. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were combined to measure the association between MIF promoter polymorphisms and cancer risk. The pooled ORs were performed for the dominant model, recessive model, allelic model, homozygote comparison, and heterozygote comparison. The publication bias was examined by Begg’s funnel plots and Egger’s test. A total of ten studies enrolling 2,203 cases and 2,805 controls met the inclusion criteria. MIF (−173G/C) polymorphism was significantly associated with increased cancer risk under the dominant model (OR=1.32, 95%, CI=1.00–1.74, P=0.01) and the heterozygote comparison (OR=1.38, CI=1.01–1.87, P=0.04). In subgroup analysis, MIF polymorphism and prostate were related to increased risk of prostate and non-solid cancer. In conclusion, MIF polymorphism was significantly associated with cancer risk in heterozygote comparison. The MIF −173G/C polymorphism may be associated with increased cancer risk.

show abstract

Recent Applications of Azo Dyes: A Paradigm Shift from Medicinal Chemistry to Biomedical Sciences

Khan

Parmar²,

Das³

2021

MRMC

View full text Add to dashboard Cite

Abstract:: Azo molecules are one of the fascinating organic molecular architectures with azo bond (-N=N-). Since the last century, the bright colored azo molecules are used as dyes for printing, food, paper, cosmetic laser, electronics, optics, material sciences etc. After the discovery of Prontosil as an antibacterial drug, azo molecules became into limelight in medicinal chemistry. Later a number of azo molecules such as Phenazopyridine, Basalazide, Sulfasalazine etc., occupied the drug market. Many azo molecules have been demonstrated as antibacterial, anti-malarial, antifungal, antioxidant, antiviral agents and many more. Metabolic degradation of many azo dyes can cause problem to liver that limits the application of azo dyes in medicinal chemistry. Azo dyes are significantly used in cancer chemotherapy. Recently, a paradigm shift has been observed in the application of azo dyes from medicinal chemistry to biomedical science area. The application of azo molecules in biomedical science such as imaging, drug deliver, photo pharmacology and photo switch areas are reported. In this article, we have complied and discussed the recent work done on azo dye molecules for medicinal importance and future prospects.

show abstract

Novel Arylazoarylmethane as Potential Inhibitor of Macrophage Migration Inhibitory Factor

Cited by 3 publications

References 27 publications

Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor

Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor

The association between the migration inhibitory factor -173G/C polymorphism and cancer risk: a meta-analysis

Recent Applications of Azo Dyes: A Paradigm Shift from Medicinal Chemistry to Biomedical Sciences

Contact Info

Product

Resources

About